Unselected bone-marrow-derived mononuclear cells seem to improve left ventricular function and perhaps short-term clinical outcomes for patients with acute myocardial infarction. The REGENT trial aimed to elucidate whether infusion of selected hematopoetic progenitor cells increases this effect in patients with large infarcts and attenuated left ventricular ejection fraction.
- Rasmus S. Ripa
- Jens Kastrup